Drug Profile
Cosibelimab - Checkpoint Therapeutics
Alternative Names: Anti PDL1 monoclonal antibody; CK 301; TG 1501Latest Information Update: 27 Mar 2024
Price :
$50
*
At a glance
- Originator Dana-Farber Cancer Institute
- Developer Checkpoint Therapeutics; TG Therapeutics Inc
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Squamous cell cancer
- Phase III Non-small cell lung cancer
- No development reported Cancer; Chronic lymphocytic leukaemia; Lymphoma; Richter's syndrome
Most Recent Events
- 22 Mar 2024 Checkpoint Therapeutics intends to resubmit Biologics License Application for cosibelimab in the mid-year 2024
- 28 Feb 2024 No recent reports of development identified for phase-I development in Cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Recurrent, Treatment-naive) in Australia (IV, Injection)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Cancer(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Recurrent, Treatment-naive) in France (IV, Injection)